Johnson & Johnson $JNJ Shares Acquired by Stokes Family Office LLC

Stokes Family Office LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 58,352 shares of the company’s stock after acquiring an additional 750 shares during the period. Stokes Family Office LLC’s holdings in Johnson & Johnson were worth $8,913,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. GFG Capital LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $35,000. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson during the 1st quarter valued at approximately $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $48,000. Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $52,000. Finally, Pandora Wealth Inc. acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $65,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ stock opened at $186.50 on Friday. The stock has a market cap of $449.34 billion, a P/E ratio of 18.00, a P/E/G ratio of 2.19 and a beta of 0.38. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48. The business has a fifty day simple moving average of $184.25 and a 200-day simple moving average of $168.63.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday, October 3rd. Raymond James Financial raised their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $199.05.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.